Targeting HIV reverse transcriptase for anti-AIDS drug design: Structural and biological considerations for chemotherapeutic strategies

Drug Design and Discovery

Volumn 13, Issue 3-4, 1996, Pages 29-47

  Arnold, Edward ^a   Das, Kalyan ^a   Ding, Jianping ^a   Yadav, Prem N S ^a,b   Hsiou, Yu ^a   Boyer, Paul L ^c   Hughes, Stephen H ^c  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; Drug resistance; Inhibition mechanism; Polymerase structure; Protein drug interactions; Structure based drug design

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; ZIDOVUDINE;

CONFERENCE PAPER; DRUG DESIGN; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; ENZYME CONFORMATION; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN;

BINDING SITES; DRUG DESIGN; DRUG RESISTANCE; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0029977510     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Goff, S.P. (1990) Retroviral reverse transcriptase: Synthesis, structure, and function. J. Acquired Immune Deficiency Syndromes, 3, 817-831.
2. Jacobo-Molina, A. and Arnold, E. (1991) HIV reverse transcriptase structure-function relationships. Biochemistry, 30, 6351-6361.
3. Whitcomb, J.M. and Hughes, S.H. (1992) Retroviral reverse transcription and integration: Progress and problems. Ann. Rev. Cell Biol., 8, 275-306.
4. Le Grice, S.F.J. Human immunodeficiency virus reverse transcriptase. (1993) In. Skalka AM, Goff SP, ed. Reverse Transcriptase. pp. 163-191. Plainview, New York: Cold Spring Harbor Laboratory Press.
5. Erickson, J.W. (1995) The not-so-great escape. Nature Struct BioL, 2, 523-529.
6. Coffin, J.M. (1995) HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science, 267, 483-489.
7. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M. and Markowitz, M. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126.
8. Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer, S., Nowak, M.A, Hahn, B.H., Saag, M.S. and Shaw, G.M. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122.
9. Kleim, J.-P., Bender, R., Billhardt, U.-M., Meichsner, C., Riess, G., Rosner, M., Winkler, I. and Paessens, A. (1993) Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother., 37, 1659-1664.
10. Kleim, J.-P., Bender, R., Kirsch, R., Meichsner, C., Paessens, A. and Riess, G. (1994) Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology, 200, 696-701.
11. Najera, I., Holguin, A., Quinones-Mateu, M.E., Munoz-Femandez, M.A., Najera, R. and Lopez-Galindez, C., Domingo, E. (1995) pol Gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. J, ViroL, 69, 23-31.
12. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. and Steitz, T.A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-1790.
13. Smerdon, S.J., Jager, J., Wang, J., Kohlstaedt, L.A., Chirino, A.J., Friedman, J.M., Rice, P.A. and Steitz, T.A. (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci USA, 91, 3911-3915.
14. Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling. J., Darby, G., Jones, Y., Stuart, D. and Stammers, D. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol., 2, 293-302.
15. Ding, J., Das, K., Tantillo, C., Zhang, W., Clark, A.D., Jr., Jessen, S., Lu, X., Hsiou, Y., Jacobo-Molina, A., Andries, K., Pauwels, R., Moereels, H., Koymans, L., Janssen, P.A.J., Smith, R., Koepke, M.K., Michejda, C., Hughes, S.H. and Arnold, E. (1995) Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure, 3, 365-379.
16. Ding. J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P.A.J., Hughes, S.H. and Arnold, E. (1995) Structure of HIV-1 RT/TIBO R 86183 reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Strcut. Biol., 2, 407-415.
17. Jacobo-Molina, A., Ding, J., Nanni, R.G., Clark, A.D., Jr., Lu, X., Tantillo, C., Williams, R.L., Kamer, G., Ferris, A.L., Clark, P., Hizi, A., Hughes, S.H. and Arnold, E. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl. Acad. Sci. USA, 90, 6320-6324.
18. Rodgers, D.W., Gamblin, S.J., Harris, B.A., Ray, S., Culp, J.S., Hellmig, B., Woolf, D.J., Debouck, C. and Harrison, S.C. (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad Sci. USA, 22, 1222-1226.
19. Jager, J., Smerdon, S., Wang. J., Boisvert, D.C. and Steitz, T.A. (1994) Comparison of three different crystal forms shows HIV-1 reverse transcriptase displays an internal swivel motion. Structure, 2, 869-876.
20. Esnouf, R., Ren, J., Ross, R., Jones, Y., Stammers, D. and Stuart, D. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol., 2, 303-308.
21. Unge, T., Knight, S., Bhikhabhai, R., Lovgren, S., Dauter, Z., Wilson, K. and Strandberg, B. (1994) 2.2 Å resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains). Structure, 2, 953-961.
22. Majumadar, C., Abbotts, J., Broder, S. and Wilson, S.H. (1988) Studies on the mechanism of human immunodeficiency virus reverse transcriptase: Steady-state kinetics, processivity and polynucleotide inhibition. J. Biol. Chem , 263, 15657-15665.
23. Kati, W.M., Johnson, K.A., Jerva, L.F. and Anderson, K.S. (1992) Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem., 267, 25988-25997.
24. Boyer, P.L., Tantillo, C., Jacobo-Molina, A., Nanni, R.G., Ding, J.. Arnold, E. and Hughes, S.H. (1994) The sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA, 91, 4882-4886.
25. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R.G., Boyer, P.L., Hughes, S.H., Pauwels, R., Andries, K., Janssen, P.A.J. and Arnold, E. (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J. Mol. Biol., 243, 369-387.
26. Patel, P.H., Jacobo-Molina, A., Ding, J., Tantillo, C., Clark, A.D., Jr., Raag, R., Nanni, R.G., Hughes, S.H. and Arnold, E. (1995) Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry, 34, 5351-5363.
27. Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M.J., Breslin, H.J., Raeymaeckers, A., Van Gelder, J., Woestenborghs, R., Heykants, J., Schellekens, K., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 343, 470-474.
28. Merluzzi, V.J., Hargrave, K.D., Labadia, M., Grozinger, K., Skoog, M., Wu, J.C., Shih, C.-K., Eckner, K., Hattox, S., Adams, J., Rosenthal, A.S., Faanes, R., Eckner, R.J., Koup, R.A. and Sullivan, J.L. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science, 250, 1411-1413.
29. Romero. D.L., Busso, M., Tan, C.-K., Reusser, F., Palmer, J.R., Poppe, S.M., Aristoff, P.A., Downey, K.M., So, A.G., Resnick, L. and Tarpley, W.G. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad, Sci. USA. 88, 8806-8810.
30. Balzarini, J., Perez-Perez, M.-J., San-Felix, A., Velazquez, S., Camarase, M.-J. and De Clercq, E. (1992) 2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother, 36, 1073-1080.
31. Pauwels, R., Andries, K., Debyser, Z., Van Dable, P., Schols. D., Stoffels, P., De Vreese, K., Woestenborghs, R., Vandamme, A -M , Janssen, C.G.M., Anne, J , Cauwenbergh, G., Desmyter, J., Heykants, J., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl Acad. Sci. USA. 90, 1711-1715.
32. Smith, M.B.K., Rouzer, C.A., Taneyhill, L.A., Smith, N.A., Hughes, S.H., Boyer, P.L., Janssen, P.A.J., Moereels, H., Koymans, L., Arnold, E., Ding, J., Das, K., Zhang, W., Michejda, C.J. and Smith, R.H., Jr. (1995) Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity. Protein Science, 4, 2203-2222.
33. Spence, R.A., Kati, W.M., Anderson, K.S. and Johnson, K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science, 267, 988-993.
34. Richman, D.D. (1993) Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother., 37, 1207-1213.
35. De Clercq, E. (1994) HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol., 47, 155-169.
36. Larder, B.A. (1994) Interactions between drug resistance mutations in human immunodeficiency virus type I reverse transcriptase. J. Gen Virol., 75, 951-957.
37. Kimberlin, D.W., Coen, D.M., Biron, K.K., Cohen. J.L. Lamb, R.A., McKinlay, M., Emini, E.A. and Whitley, R.J. (1995) Molecular mechanisms of antiviral resistance. Antiviral Res., 26, 369-401.
38. Boyer, P.L., Ding, J., Arnold, E. and Hughes, S.H. (1994) Drug resistance of human immunodeficiency virus type 1 reverse transcriptase: Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother, 38, 1909-1914.
39. 138→Lys on the p51 subunit. J. Biol. Chem., 269, 25255-25258.
40. Havlir, D., Cheeseman, S.H., McLaughlin, M., Murphy, R., Erice, A., Spector, S.A., Greenough, T.C., Sullivan, J.L., Hall, D., Myers, M., Lamson, M. and Richman, D.D. (1995) High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection, J. Infect. Dis., 171, 537-545.
41. Pauwels, R., Andries, K., Debyser, Z., Kukla, M.J., Schols, D., Breslin, HJ., Woestenborghs, R., Desmyter, J., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. (1994) New TIBO derivatives are potent inhibitors of HIV-1 replication and are synergistic with 2′,3′-dideoxynucleoside analogues. Antimicrob. Agents Chemother., 38, 2863-2870.
42. Kashman, Y., Gustafson, K.R., Fuller, R.W., Cardellina, J.H., II, McMahon, J.B., Currens, M.J., Buckheit, R.W.J., Hughes, S.H., Cragg, G.M. and Boyd, M.R. (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum langericum. J. Med. Chem., 35, 2735-2743.
43. Boyer, P.L., Currens, M.J., McMahon, J.B., Boyd, M.R. and Hughes, S.H. (1993) Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol., 67, 2412-2420.
44. Goldman, M.E., O'Brien, J.A., Ruffing, T.L., Schleif, W.A., Sardana, V.V., Bynes, V.W., Condra, J.H., Hoffman, J.M. and Emini, E.A. (1993) A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency type 1 isolates resistant to related inhibitors. Antimicrob. Agents Chemother., 37, 947-949.
45. Kellam, P., Boucher, C.A. and Larder, B.A. (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA, 89, 1934-1938.
46. Martin, J.L., Wilson, J.E., Haynes, R.L. and Furman, P.A. (1993) Mechanism of human immunodeficiency virus type 1 resistance to dideoxyinosine. Proc. Natl. Acad. Sci. USA, 90, 6135-6139.
47. Lacey, S.F., Reardon, J.E., Furfine, E.S., Kunkel, T.A., Bebenek, K., Eckert, K.A., Kemp, S.D. and Larder, B.A. (1992) Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem., 267, 15789-15794.
48. Larder, B.A. (1992) 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother., 36, 2664-2669.
49. Nanni, R.G., Ding. J., Jacobo-Molina, A., Hughes, S.H. and Arnold, E. (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspectives in Drug Discovery and Design, 1, 129-150.
50. Mellors, J.W., Bazmi, H.Z., Schinazi, R.F., Roy, B.M., Hsiou, Y., Arnold, E., Weir, J. and Mayers, D.L. (1995) Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother., 39, 1087-1092.
51. Boy er, P.L. and Hughes, S.H. (1995) Analysis of mutations at position 184 in the reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 39, 1624-1628.
52. St. Clair, M.H., Martin, J.L., Tudor-Williams, G., Bach, M.C., Vavro, C.L., King, D.M., Kellam, P., Kemp, S.D. and Larder, B.A. (1991) Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science, 253, 1557-1559.
53. Shafer, R.W., Kozal, M.J., Winters, M., Iversen, A.K.N., Katenstein, D.A., Ragni, M.V., Meyer, W.A.I., Gupta, P., Rasheed, S., Coombs, R., Katzman, M., Fiscus, S. and Merigan, T.C. (1994) Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis., 169, 722-729.
54. Shirasaka, T., Kavlick, M.F., Ueno, T., Gao, W.-Y., Kojima, E., Alcaide, M.L., Chokekijchai, S., Roy, B.M., Arnold, E., Yarchoan, R. and Mitsuya, H. (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA, 92, 2398-2402.
55. Larder, B.A. (1992) AZT resistance suppressed by a mutation conferring HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother, 36, 1171-1174.
56. Chow, Y.-K., Hirsch, M., Merrill, D.P., Bechtel, L.J., Eron. J.J., Kaplan, J.C. and D'Aquila, R.T. (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature, 361, 650-654
57. Emini, E.A., Graham, D.J., Gotlib, L., Condra, J.H., Byrnes, V.W. and Schleif, W.A. (1993) HIV and multidrug resistance. Nature, 364, 679.
58. Larder, B.A., Kellam, P. and Kemp. S.D. (1993) Convergent combination therapy can select viable multidrug resistant HIV-1 in vitro. Nature, 365, 451-453.
59. Larder, B.A. Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. (1993) In: Skalka AM, Goff SP, ed. Reverse Transcriptase. pp. 205-222. Plainview, New York: Cold Spring Harbor Laboratory Press.
60. Rittinger, K., Divita, G. and Goody, R. (1995) Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. P roc Natl. Acad. Sci. USA. 92, 8046-8049.
61. Georgiadis, M.M., Jessen, S.M., Ogata, C.M., Telesnitsky, A., Goff, S.P. and Hendrickson, W.A. (1995) Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. Structure. 3, 879-892.
62. Ren, J., Esnouf, R., Hopkins, A., Ross, C., Jones, Y., Stammers, D. and Stuart, D. (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure, 3, 915-926.